Variant Bio Expands Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular Disease

Expanded, multi-year collaboration applies Variant Bio's AI-powered Inference platform to cardiovascular target discovery Variant Bio is eligible for additional upfront, platform access and milestone payments for a total deal value potentially exceeding $250 million SEATTLE, Sept. 23,...